have impacted to to tools the your needs our we COVID-XX. of steps joining a I'd call disease. from extending suffering the to COVID-XX the who this by aspects The central you, the with you have including those each wishes Matt. provide the and treat the by families upended open mitigate for of taken presented as Thank like my to to all as PAD, afternoon unprecedented the deal physicians health care businesses, procedures the of you and many spread us. Good pervasive lives, and daily nation challenges virus thank best for of
While of the steps shelter is degrees degree or some orders. distancing are first of varying still much of several under taking the social U.S. states in resuming toward place normalcy,
quarter very prior in impact we drive to into today, disclosed opening will quarter April, strong COVID-XX. the off a remarks business the exciting the was start the And perspective a provide of will also on second to our developments call business of the first our we first XXXX half and to cover our will that the the quarter, on number of our in effects As key how and responded on second in milestones believe we've we pandemic's XXXX. while
efforts model a and growth Setting the sales we successful prioritize and commercialization account new evolved of products to focused on new bit, product our our throughout XXXX, business disposable in acquisition. stage our
momentum as in As from reliance prior significantly and sales. products a as capital of we objectives. and working on our year-end were we've result, continued in This business to we years, our legacy these better efforts, our appears success on to be strategy move deliver increased that demonstrating continue than benefits reported to results away scale the markets large
health access to Pantheris January year, metric eliminated COVID-XX XXXX. grew revenue increased first or in And encouraging, numbers of care rates of the since activity million. XX% March February, from and growth of in procedures. pandemic first over the by states in prior by onset higher Disposable elective to XX% the case positive Total the also of rapid and the These much reflect reduced are they decline in as revenue at XX% the case sales prior to trend key $X.X increased activity. Looking quarter quarter a XXXX. continuing a
In strategy. growth Adding third and progress made the the new new accounts in significant our second sites half sites, such Louisiana. We including Arizona, element increased of XX of in of we XXXX, in launch continues combined. locations high-volume first with clinical Lumivascular fourth of to and quarter as be our the adding area a in quarter, Michigan pace new states new this acquisition XX account key the
the been marketplace, momentum atherectomy we've illustrates the including to gaining the Pantheris interest new products, in This in strong due our SV.
the technologies. to downturn, begin centers continue base during we time to effort current have more on looking as to are customer and a a little physicians customers, the available reopen. learn about who And marketing We Avinger's grow Lumivascular to solution focused have our to
and very to well product perform commercial front, in SV the the a from perspective both Pantheris clinical On continued quarter. first
this now an from believe longer that smaller position positive. with and safely a than SV competitive and driving unique one new its addressable overwhelmingly of to marketplace, us the as profile gives Lumivascular Pantheris much of compelling products field shipped that accounts length We expands device feedback knee underserved lesions familiarity is as to we lower our in treat physicians the increasing SV's enable approach believe also the vessels XX We and more and market our variety have the in below exciting by usage and XX%. across a family by the PAD benefits. area
new in our progress of We Ocellaris, development image-guided to the our catheter. including next-generation of also products, continue make CTO-crossing significant pipeline
December new successful XXXX recall first the are we or our the received and knee. a that below arteries. the CTOs, after blocked a of Europe both belief types treatment changer arteries in game in this peripheral across and reinforced Those lesion that Marking which device total in the is product of cases completely early above Ocellaris chronic procedures variety occlusions completed with soon might in You for CE this
our user-controlled speeds ability CTOs. précised of designed imaging, real-time range crossing all up improvements lumen, video is to a RPM for bring the we platform, enhance to Ocellaris XXXX for within will and wider true maneuverability rate of tip rotational believe including which physician's to several a of luminal deflectable
for XXX(k) premarketing clearance, caused contributor on to be of disruptions case hope to restrictions FDA this our market of are the we that recent increased available we quarter our Pending quarter. as the this hopeful are procedures in normal a submission by launch across year. states with markets COVID-XX, filing and more this growth U.S. achieve to of on and will track in spite FDA clearance, elective we Ocellaris more for In with our remain Timely lab as operations. return lifted a will the activity also key fourth coincide goal schedules cath revenue
invest next-generation We console to of the development LXXX accelerated Lightbox. also imaging continue the in our
the OCT powerful we next-generation provide also Our future LXXX is and software be through imaging use a state-of-the-art solid-state system. It's to platform system high-speed deliver believe could catheter our advanced a rotation, catheter proprietary more variable designed of to for applications. computing designed laser, important which
deliver than providing cost-efficient mountable and we that by portable, reduced cath XX this existing a size enhanced shipping efficient environment a be fitness-sized capability standard our through believe transport design integration image pole carrier IV radically we to into for within weight standard and and the clinical pounds, configuration. carry-on-case, and weigh easy LXXX highly specialists, overnight sales reps lab final banks. exciting, Most on and the less We can anticipate an
Lightbox provide a overcoming our significant cost We to also to reduction the expect current to a entry. LXXX key barrier compared
to account broaden customer positive image-guided have these a enhancements strategy a all of will new We believe expansion our of of on impact wide platform and accounts. a provide acquisition, more that range service efficient
in to in year. prior anticipate be end product to months the expect being XXX(k) the of a validation We position at in FDA submission and position to a with this to upcoming complete the a point file the
to this the of continue trial, and we side, our make the completing the on in enrollment patients INSIGHT We being the first clinical and The a restenosis in data application the extremity anticipate this treatment presented encouraging. arteries. in-stent ISR to or our was XXX(k) IDE lower enrolled year. end clinical was preliminary to in to of On INSIGHT important for label position ISR study indication expand Pantheris year progress from the highly study by submit a in include evaluating last
the peripheral initiated to January, for of to called the Pantheris post-market is end in we more INSIGHT, COVID-XX patient to clinical below to IMAGE-BTK normal announced progress year, SV in we resume addition new IMAGE-BTK. study trial, In of efficacy half that and safety study our in we points first return when case a been levels. This treatment in expect evaluate had designed artery enrollment a paused lesions and of second due SV the has to knee. the Pantheris activities for
We how for more change. will update information have study you as the will this on we schedule
put activity for business in issued in the the in our Medicaid guidelines and impact with medical case by & General and restrictions Services state rapidly, and Centers to March, elective and procedures began providers local as COVID-XX governments. guidance Surgeon -- or deferred Medicare the accordance hospitals declining with place U.S. earlier, by the discussed As
of and restricted measures addition, access support patients they resources clinical staff, the spread representatives In as hospitals treatment the and prioritize to COVID-XX virus. limit of the many take sales for for
to continued see second XX% more the in first in quarter. volume these overall with quarter, of impact restrictions weeks than the We've the of up by case the
as our been more the to severe cases, most centers of treatment and that every critical for in lead While be tissue CLI, deferred, left image-guided of day loss devices such noncritical a limb ischemia form have to used hospitals untreated. urgent if PAD procedures outpatient continue limb or can and
compliance the with invitation is of cases, guidelines. hospital our these most in the present treating of In staff and clinical physician at support
the when return more we care loosen normal see the we elective latter case into and non-critical see to see in states more continue procedures to of towards quarter system, this in case in As steps quarter the volumes. hope are third health activity to and restrictions and and second improvement to part the positive available resources improvement on starting the become an expect
as COVID-XX expect second throughout impacted the significantly However, by revenue we our communicated to quarter. previously be
time, and also future to to maintain now efforts. and current with customers cases our be and the to customers in strong case marketing through communication priority volumes broader During continued their We've ready our improve. our and potential this support a as connection physician to is direct outreach available
kicked the week physician-focused a was series of treatment initiated of attended below-the-knee over virtually session last by physicians off opinion leader lesions by a led We've on with physicians. series this that webinars key XX and
We as are physicians strengthen clinical Lumivascular referral And our sites. our and current we a prepare for and training volumes. podiatrists return organization also programs to referring targeting to implemented teams virtual for for conducting higher our sales other we've meetings
be critical patients our continue field-based PAD. strategic advance of with commercialization importantly limb the continue could support to physicians by teams more as of effectively deal products next-generation life-saving our the work treating proud our and including COVID-XX headquarters with and presented their to most we in not and initiatives I challenges
from disruption we've moments, our these second period, the will cost half our taken Mark give flexibility COVID-XX. steps the and the in actions believe of resources during needed As to runway We reduce the also address us will through a to increase this year. response structure in few and cash to navigate
we volumes customer sites. through be resume capabilities our rapidly new increase returns label a market and in addition of to to new case As position and demand expect indications, new opportunity full grow products, and market the
to At this financials for point Q&A. come I'd I'll then and to back like cover ask Mark our Mark?
